# A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Study · id `cardio:ct-nct05646381` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05646381](<https://clinicaltrials.gov/study/NCT05646381>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05646381

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 502 participants.

## Technical summary

Registry record NCT05646381. Randomized; double masking; primary purpose treatment. Start 2024-03-07 (actual); primary completion 2030-03-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 502 participants (planned count; ClinicalTrials.gov record NCT05646381, source copy `cardio:ctgov-nct05646381-2026-06-23`, retrieved 2026-10-26)
- Started: 2024-03-07 (actual) (ClinicalTrials.gov record NCT05646381, source copy `cardio:ctgov-nct05646381-2026-06-23`, retrieved 2026-10-26)
- Primary completion: 2030-03-12 (anticipated) (ClinicalTrials.gov record NCT05646381, source copy `cardio:ctgov-nct05646381-2026-06-23`, retrieved 2026-10-26)
- Completion: 2030-03-12 (anticipated) (ClinicalTrials.gov record NCT05646381, source copy `cardio:ctgov-nct05646381-2026-06-23`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Canada; Czechia; Denmark; France; Germany; Israel; Italy; Netherlands; Portugal; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT05646381, source copy `cardio:ctgov-nct05646381-2026-06-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05646381-2026-06-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- Condition: Aortic Stenosis
- Intervention (Drug): Pelacarsen (TQJ230) 80mg
- Intervention (Drug): Matching placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: f86e14f725abf84e290286f09eeed55894c0ab2219309fbdede67863691ea199
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
